Presentations

MN-166 (ibudilast) Presentations

MN-166 (ibudilast) Presentations

Progressive Multiple Sclerosis (Progressive MS):

MN-166 (ibudilast) for Progressive MS: SPRINT-MS Phase 2b Trial AAN 2018 Presentation (1.5 MB)

MN-166 (ibudilast) for Progressive MS: SPRINT-MS Phase 2b Trial Disability Data ACTRIMS 2018 Poster (0.4 MB)

MN-166 (ibudilast) for Progressive MS: SPRINT-MS Phase 2b Trial Top-Line Results ECTRIMS 2017 Presentation (1 MB)

MN-166 (ibudilast) for Progressive MS: American Academy of Neurology (AAN) 2015 Poster (0.5 MB)

Amyotrophic Lateral Sclerosis (ALS):

MN-166 (ibudilast) for ALS: American Academy of Neurology (AAN) 2018 Poster (2.2 MB)

MN-166 (ibudilast) for ALS: International Symposium on ALS-MND 2017 Presentation (4.8 MB)

Glioblastoma:

MN-166 (ibudilast) for Glioblastoma: American Society of Clinical Oncology (ASCO) 2017 Poster (10 MB)

Substance Dependence and Addiction:

MN-166 (ibudilast) for Opioid Dependence: American Academy of Neurology (AAN) Poster (0.4 MB)

MN-166 (ibudilast) for Methamphetamine Dependence: College on Problems of Drug Dependence (CPDD) Poster (0.4 MB)

MN-166 (ibudilast) for Alcohol Dependence: American College of Neuropsychopharmacology (ACNP) Poster (0.7 MB)

MN-166 (ibudilast) News Articles

SPRINT-MS: Ibudilast Shows Unprecedented Slowing of Brain Atrophy in Progressive MS

New Drug Shows Promise in Slowing Progressive MS

MN-166 (ibudilast) Publications

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R; MN166-001 Investigators.
Neurology. 2010 Mar 30;74(13):1033-40. doi: 10.1212/WNL.0b013e3181d7d651. Epub 2010 Mar 3.
PMID: 20200338

Primary neuroprotection: the Holy Grail of multiple sclerosis therapy.
Fox RJ.
Neurology. 2010 Mar 30;74(13):1018-9. doi: 10.1212/WNL.0b013e3181d6b165. Epub 2010 Mar 3. No abstract available.
PMID: 20200341

Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia.
Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, Suzumura A.
Neuropharmacology. 2004 Mar;46(3):404-11.
PMID: 14975696

Ibudilast protects against neuronal damage induced by glutamate in cultured hippocampal neurons.
Tominaga Y, Nakamura Y, Tsuji K, Shibata T, Kataoka K.
Clin Exp Pharmacol Physiol. 1996 Jun-Jul;23(6-7):519-23.
PMID: 8800577

Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS.
Suzumura A, Ito A, Yoshikawa M, Sawada M.
Brain Res. 1999 Aug 7;837(1-2):203-12.
PMID: 10434004

Phosphodiesterase inhibitors suppress IL-12 production with microglia and T helper 1 development.
Suzumura A, Ito A, Mizuno T.
Mult Scler. 2003 Dec;9(6):574-8.
PMID: 14664469

Cyclic AMP-elevating agents prevent oligodendroglial excitotoxicity.
Yoshioka A, Shimizu Y, Hirose G, Kitasato H, Pleasure D.
J Neurochem. 1998 Jun;70(6):2416-23.
PMID: 9603206